MLS Bio Closes Oversubscribed Angel SAFE Note at AUD $1M and Launches US$25M Series A to Advance Oncology Programs.

MLS Bio’s Board today announced the successful close of its Angel SAFE Note round, oversubscribed at AUD $1 million, with significant support from both the Melbourne Angels and Perth Angels investor groups. The oversubscription highlights strong confidence in MLS Bio’s pipeline and strategy as the company transitions into its next growth phase.

Building on this momentum, MLS Bio has formally launched its Series A financing round, targeting US$25 million. Proceeds will be directed towards:

• Completion of toxicology studies across oncology and antiviral assets
• Regulatory preparation, including FDA Pre-IND submissions
• Establishment of commercial operations and expansion of governance infrastructure
• Phase 1b/2 clinical trials for MLS-269, the company’s lead oncology asset in prostate cancer, to be conducted in collaboration with the globally leading Prostate Cancer Clinical Trials Consortium (PCCTC)
• Strategic international expansion, including U.S.-based Board and SAB appointments

“Closing our Angel SAFE Note oversubscribed reflects the market’s strong validation of our scientific platform and governance progress,” said Penelope Lane, Managing Director & CEO of MLS Bio. “The launch of our Series A is the next pivotal step, enabling us to advance MLS-269 into clinical development while building the commercial and regulatory foundations required to become a globally competitive biotech company.”

Interested investors are invited to contact Ms. Penelope Lane, CEO & Managing Director, for further details.

Contact:

Ms Penelope Lane

Chief Executive Officer & Managing Director

📧 Penelope@mlsbio.com